Mobolt works at the frontier of life sciences and technology — identifying, building, and supporting ventures that will define how we understand and improve human health.
Machine learning and foundation models are beginning to transform clinical workflows, diagnostics, and drug discovery. We focus on applications where AI meaningfully improves outcomes — not just efficiency.
From genomics to protein engineering, the tools of biology have never been more precise or programmable. We engage with founders building platforms that extend what is biologically possible.
Great science requires great companies. We support the builders — operators, researchers-turned-founders, and technical teams — navigating the leap from discovery to durable organization.
Software, devices, and data platforms are reshaping how patients interact with care systems. We look for solutions that address structural gaps — access, continuity, and meaningful personalization.
Biology and computation are converging faster than institutions can adapt. Sequencing costs have collapsed, AI models can reason over protein structures and clinical text, and a new generation of founders is trained in both domains. The result is a rare window where foundational problems in human health — cancer, aging, rare disease, mental health — are genuinely tractable in ways they were not a decade ago.
Mobolt exists at this intersection. We believe the most important companies of the next decade will be built by people who understand both the science and the systems around it. Our work is to find those people early, provide the context and connections they need to move faster, and stay engaged through the long arc of building something that lasts.
Whether you're building in this space, researching it, or looking to work together — we'd like to hear from you.